中国实用内科杂志2024，Vol.44Issue(1)：64-67,4.DOI:10.19538/j.nk2024010112
罗沙司他治疗病毒性肝炎维持性血液透析合并肾性贫血患者临床疗效及安全性
Clinical efficacy and safety of Roxadustat in the treatment of renal anemia in patients with undergoing maintenance hemodialysis combined with viral hepatitis
摘要
Abstract
Objective To explore the clinical efficacy and safety of hypoxic inducible factor prolyl hydroxylase inhibitors—Roxadustatin patients with viral hepatitis undergoing maintenance hemodialysis and renal anemia.Methods 30 patients with viral hepatitis undergoing maintenance hemodialysis,renal anemia and poor therapeutic effect of erythropoietin from the Blood Purification Center of Tianjin First Central Hospital from January to December in 2022 were selected and treated withRoxadustatfor 12months.The changes of anemia compliance rate,anemia index,iron metabolism index and related physicochemical index before and after adjustedmedication were compared.Results After 12 months of treatment with Roxadustat,the total hemoglobin compliance rate was 93.3％.The anemia related indicators of patients after treatment include hemoglobin[109.50(102.25,115.00)g/L vs.117.50(113.25,124.75)g/L],Z=4.329,P＜0.001;red blood cell specific volume[(0.30±0.05)％vs.(0.38±0.06)％,t=3.670,P=0.001],and red blood cell count[(3.16±0.60)×1012/L vs.(3.59±0.69)×1012/L,t=5.540,P＜0.001]were increased compared to before treatment,and the difference was statistically significant.The iron metabolism related indicators of patients after treatment include serum iron[9.90(8.32,13.18)]μmol/L vs.13.45(10.80,19.30)μmol/L,Z=3.451,P=0.001],and transferrin saturation[28.35(21.94,33.06)％vs.33.63(26.37,38.95)％,Z=3.211,P=0.001]significantly increased compared to before;ferritin[(274.09±147.51)μg/L vs.(184.44±92.21)μg/L,t=-4.197,P＜0.001],and hepcidin[(120.48±18.61)ng/Lvs.(83.42±16.92)ng/L,t=-3.432,P=0.002]decreased compared to before.After treatment,there was no significant change in systolic blood pressure,diastolic blood pressure,and related physicochemical indicators compared to before treatment(P＞0.05).Conclusion Roxadustat can effectively improve the anemia status of maintenance hemodialysis patients with viral hepatitis with poor treatment effect of erythropoietin,and can also improve the inflammation and iron metabolism of patients with good safety.关键词
罗沙司他/慢性肾脏病/低氧诱导因子脯氨酰羟化酶抑制剂/维持性血液透析/病毒性肝炎/肾性贫血Key words
Roxadustat/chronic kidney disease/hypoxic inducible factor prolyl hydroxylase inhibitors/maintenance hemodialysis/viral hepatitis/renal anemia分类
医药卫生引用本文复制引用
陈丽,张文玉,常文秀..罗沙司他治疗病毒性肝炎维持性血液透析合并肾性贫血患者临床疗效及安全性[J].中国实用内科杂志,2024,44(1):64-67,4.基金项目
天津市卫健委科技基金面上项目(TJWJ2021MS012)感谢中国健康促进基金会医疗服务能力建设专项基金之"慧研卓识"期刊战略合作项目的公益支持! （TJWJ2021MS012）
